Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197139 | 1.00 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL197117 | 1.00 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Ammonia Solution, Strong SCHEMBL28728215 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL21059082 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Chloromethane SCHEMBL29259265 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL28431532 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL18770586 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL4576488 | 0.89 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL27695113 | 0.89 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Leucine SCHEMBL9119565 | 0.87 | SLC7A5 (0.72) | SLC7A5GRIK1SLC1A2SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1710 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOC DES PRODUITS NESTLE S A (CH) | 2026-05-21 | — | — | US | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250281438-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-11 | — | — | US | claimed |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-26 | — | — | US | claimed |
| WO-2025120217-A2 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | claimed |
| WO-2025120219-A2 | NOVEL POLYPEPTIDES | ONCOPEPTIDES INNOVATION 1 AB (SE) | 2025-06-12 | — | — | WO | claimed |
| EP-4493273-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | Politechnika Wroclawska (PL) | 2025-01-22 | — | — | EP | claimed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| EP-4440563-A1 | COMPOSITIONS AND METHODS USING AN AMINO ACID BLEND FOR PROVIDING A HEALTH BENEFIT IN AN ANIMAL | Société des Produits Nestlé S.A. (CH) | 2024-10-09 | — | — | EP | claimed |
| EP-0934952-A2 | Peptides containing an N-substituted glycine residue | Nisshin Flour Milling Co., Ltd. (JP) | 1999-08-11 | — | — | EP | claimed |
| EP-0931792-A1 | Depsipeptides containing non-natural amino acids | Nisshin Flour Milling Co., Ltd. (JP) | 1999-07-28 | — | — | EP | claimed |
| EP-0927723-A1 | Bicyclic depsipeptides promoting the production of apolipoprotein E | Nisshin Flour Milling Co., Ltd. (JP) | 1999-07-07 | — | — | EP | claimed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5883075-A | HYPOTENSIVE AGENT CYCLIC PEPTIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-16 | — | — | US | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| EP-0499266-B1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-07-10 | — | — | EP | claimed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | claimed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539288-B2 | Compositions and methods using at least one glycine or derivative thereof and/or at least one N-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol | LIPC, GGT1, TGM2 | SLC7A5 2505/4885PTGS1 535/4885SLC7A11 184/4885 |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | F11, F2, F12 | SLC7A5 4660/4885PTGS1 1065/4885SLC7A11 4549/4885 |
| US-20260137643-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND/OR AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE THYMOL AND/OR CARVACROL | LIPC, GGT1, TGM2 | SLC7A5 2583/4885PTGS1 497/4885SLC7A11 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.